Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals |
| |
| Affiliation: | 1. Heart Research Group, Murdoch Children''s Research Institute, Melbourne, Australia;2. Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Victoria, Australia;3. Department of Cardiac Surgery, The Royal Children''s Hospital, Melbourne, Australia;4. The Heart Centre for Children, The Children''s Hospital at Westmead, Sydney, Australia;5. Department of Paediatrics, University of Sydney, Sydney, Australia;6. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia;7. Department of Cardiology, Women''s and Children''s Hospital, Adelaide, Australia;8. Children''s Cardiac Centre, Princess Margaret Hospital for Children, Perth, Australia;9. Greenlane Paediatric and Congenital Cardiac Service, Starship Children''s Hospital, Auckland, New Zealand;10. Department of Cardiology, The Royal Children''s Hospital, Melbourne, Australia;11. Queensland Paediatric Cardiac Service, Lady Cilento Children''s Hospital, Brisbane, Queensland, Australia;12. Department of Cardiology, The Royal Melbourne Hospital, Melbourne, Australia;13. Adult Congenital Heart Unit, The Prince Charles Hospital, Brisbane, Australia;14. Faculty of Medicine, University of Queensland, Brisbane, Australia;15. Department of Gastroenterology, The Royal Children''s Hospital, Melbourne, Australia;p. Medical Imaging Department, The Royal Children''s Hospital, Melbourne, Australia;1. Department of Cardiology, Boston Children''s Hospital, Boston, MA, United States;2. Department of Medicine, Brigham and Women''s Hospital, Boston, MA, USA;3. Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College of Science and Medicine, London, United Kingdom;4. Department of Medicine, North Shore Medical Center, Salem, MA, USA;5. Adolescent and Adult Congenital Heart Disease Program, Heart Institute, Cincinnati Children''s Hospital Medical Center, Cincinnati, OH, USA;6. Pacific Adult Congenital Heart Disease Clinic, Division of Cardiology, St. Paul''s Hospital, University of British Columbia, Vancouver, British Columbia, Canada;7. Ohio State University Division of Cardiovascular Medicine and Nationwide Children''s Hospital Heart Center, Columbus, OH, USA |
| |
| Abstract: | Overwhelming post-splenectomy infection (OPSI) is immediately life-threatening and vaccination against encapsulated bacteria, in particular pneumococci, decreases its incidence.First, we investigated the adherence to vaccination guidelines in a retrospective study of the hospital records of splenectomised patients. Second, patients were asked to complete a questionnaire and invited to participate in a study where 12-valent pneumococcal serotype-specific IgG concentrations were determined before and 4 to 6 weeks after vaccination with PCV13.Of 79 individuals who underwent splenectomy between 2000 and 2012: 81.0% received pneumococcal vaccine, 51.9% received vaccine against Haemophilus influenzae type B and 22.8% received meningococcal vaccine. 31 individuals were deceased. 33 individuals completed questionnaires and accepted participation in the second part of the study. The participants consisted of two groups: (1) prior PPV23 (n = 24) and (2) prior PPV23 + PCV13 (n = 9). In group 1, pre-PCV13 GMC's ≥ 0.35 μg/mL were observed for serotypes 1, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and GMC's < 0.35 μg/mL for serotypes 3 and 5, significant increases pre- to post-PCV13 were found for serotypes 1, 3, 4, 5, 7F, 18C, 19A, 23F (p ≤ 0.001) and 19F (p = 0.01) and all 12 serotypes-specific GMC were above 0.35 μg/mL after vaccination. Group 2 did not receive vaccine in this study, but blood tests showed all 12 serotype-specific GMC > 0.35 μg/mL.Adherence to guidelines regarding primary pneumococcal vaccination was adequate but only a minority received the recommended meningococcal vaccination.High levels of pneumococcal serotype-specific antibodies were observed in the previous PPV23 vaccinated group, and more pronounced in the previous PCV13 group, and our data suggests that PCV13 is immunogenic for serotypes 1, 3, 4, 5, 7F, 18C, 19A, 19F and 23F, if used as a booster dose in asplenic patients with previous PPV23 vaccination. |
| |
| Keywords: | Pneumococcal vaccination Asplenia |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
